Back to Search Start Over

Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection

Authors :
I. Versace
Alfredo Alberti
Elisa Biliotti
D. Bartolozzi
Nicola Caporaso
P.L. Almasio
Paola Rucci
Rosa Cristina Coppola
Marco Chiaramonte
S. Zacharia
L. Cirrincione
Gloria Taliani
G. Secchi
Alfonso Mele
Marcello Persico
G. B. Gaeta
Annarosa Floreani
Alessio Aghemo
Taliani, G
Rucci, P
Biliotti, E
Cirrincione, L
Aghemo, A
Alberti, A
Almasio, Pl
Bartolozzi, D
Caporaso, Nicola
Coppola, R
Chiaramonte, M
Floreani, A
Gaeta, Gb
Persico, M
Secchi, G
Versace, I
Zacharia, S
Mele, A.
Taliani G.
Rucci P.
Biliotti E.
Cirrincione L.
Aghemo A.
Alberti A.
Almasio PL.
Bartolozzi D.
Caporaso N.
Coppola R.
Chiaramonte M.
Floreani A.
Gaeta GB.
Persico M.
Secchi G.
Versace I.
Zacharia S.
Mele A.
TALIANI G
RUCCI P
BILIOTTI E
CIRRINCIONE L
AGHEMO A
ALBERTI A
ALMASIO PL
BARTOLOZZI D
CAPORASO N
COPPOLA R
CHIARAMONTE M
FLOREANI A
GAETA GB
PERSICO
SECCHI G
VERSACE I
ZACHARIA S
MELE A
Publication Year :
2007
Publisher :
Blackwell Science Limited:PO Box 88, Oxford OX2 0NE United Kingdom:011 44 1865 776868, 011 44 1865 206038, EMAIL: journals.cs@blacksci.co.uk, INTERNET: http://www.blackwell-science.com, Fax: 011 44 1865 721205, 2007.

Abstract

Summary. Hepatitis C virus (HCV) infection is associated with a significant reduction of health related quality of life (QOL), the causes and mechanisms of which are still unknown. To explore whether treatment history could affect QOL, we examined patients with detectable HCV viraemia who had a different therapeutic background. Two hundred sixty-four consecutive subjects with chronic HCV infection and detectable viraemia were enrolled. Of these, 163 were untreated patients, 43 were relapsers, 58 were nonresponders (NR) to nonpegylated interferon (IFN) therapy. To assess QOL, three self-report instruments were employed: the Short Form-36 (SF-36), the Chronic Liver Disease Questionnaire (CLDQ-I) and the World Health Organization Quality of Life assessment (WHOQOL-BREF). Clinical and demographic data were collected, and the QOL scores of HCV-positive patients were compared with those of an Italian normative sample and healthy controls. Further antiviral treatment was offered to untreated and relapsed patients but not to NR. All patient groups displayed lower QOL scores compared with the normative sample and controls. NR displayed lower QOL scores in several areas compared with untreated patients and relapsers. In multivariate regression analyses, being NR and having a physical comorbidity were significantly associated with poorer QOL. Conclusions: Treatment history and expectations and physical comorbidity may affect QOL in HCV-positive patients. Untreated and relapsed patients have comparable levels of QOL and higher scores than NR.

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....224a405f6accf5476ca7041813edc229